Ticker: ABCL

08:38am, Monday, Aug 10, 2026

AbCellera Shares Jump 22% After Promising Menopause Treatment Trial

AbCellera's stock surged 22% following successful Phase 2 trial results for ABCL635, targeting moderate-to-severe menopause symptoms with notable improvements and strong safety data.